TS03 Inc Trust Units TSTIF

RE:Canaccord Genuity Research Report of 14 Mar 2016

[echo2]

Interesting that Desjardins suggested to buy on weakness, implying a possible negative from this news due to a confused perceived potential FDA delay in extended claims with a 3.85 target, and Canaccord more appropriately sees this FDA progress as a positive and reiterates a buy these levels but with a lower target. Both are extremely conservative, IMHO, especially Canaccord maintaining an amazing 11% discount rate and incredibly low 2% annual growth over the longer term.
Can't wait for some reputable US analysts to give a real indication of what this company is worth following the cc! As has been mentioned, some reliable US coverage and interest might soon put TOS on a lot more radar screens and in a host of portfolios south of the border. (I wonder what has happened to Rumble's consideration of a listing on Nasdaq?)
As indicated in the previous Canaccord analysis, there is considerable blue sky potential, here, and I stick by my belief that this stock is grossly undervalued and underappreciated by the present market. (Could easily reach $10 /share and $1,000,000,000 market cap CDN, if Getinge or JnJ don't move on it sooner rather than later.)
WKH